Leist Thomas P

Leist Thomas P, operating as Thomas Leist Division, is a sole proprietorship based in Wynnewood, Pennsylvania, that provides specialized medical expert services to the federal government as a prime contractor on BPA call orders, competing almost exclusively under total small business set-asides. The vendor has received 357 federal contract awards, all as prime, with 92% of awards concentrated at the Department of Health and Human Services' Health Resources and Services Administration for vaccine injury compensation program work.

Leist Thomas P's entire operational footprint centers on medical case review, expert analysis, and expert testimony in support of the Vaccine Injury Compensation Program (VICP) and Countermeasures Injury Compensation Program (CICP). The vendor operates under NAICS 5191 (Offices of Physicians except Mental Health Specialists) and PSC code Support-Professional: Expert Witness, reflecting a narrow but deeply specialized capability. Representative task orders include a $24,375 BPA call from HRSA dated August 25, 2026, for medical case reviewer services on VICP and CICP claims; a $6,000 call from December 4, 2024, for medical expert services including case review, expert reports, and testimony; and a $9,375 call from November 17, 2022, for specialized medical expert review and opinion to aid HRSA in adjudicating individual VICP claims. Over 90% of recent task orders carry total small business set-aside designations, with the remainder on unrestricted set-asides.

Customer concentration is extreme. HRSA Headquarters accounts for 325 of 357 awards (92% of the portfolio) and $22 million of the $22 million combined potential value; the Department of Justice Civil Division holds three awards worth $24,000. The vendor's work flows through five primary BPA vehicles: HHSH250201400042B (125 task orders, $325,000 combined potential), HHSH234200851018B (106 task orders, $195,000 combined potential), 75R60219A00032 (57 task orders, $148,000 combined potential), 75R60221A00030 (52 task orders, $227,000 combined potential), and 75R60224A00007 (9 task orders, $80,000 combined potential). These BPAs, held directly by Leist Thomas P with HRSA, are the sole mechanism for federal work; the vendor holds no membership on government-wide IDIQs, GWACs, or civilian-agency vehicles outside HRSA.

Activity has declined sharply. The vendor averaged 23 awards per year from 2022 through 2023, dropped to seven in 2024, three in 2025, and one in 2026. Over the next twenty-four months, only one award worth $24,000 faces ultimate completion and recompete exposure. Combined potential value across all 357 awards stands at $22 million, but obligated dollars total only $1.1 million (5% of potential), indicating most task orders are issued incrementally at modest per-case values ranging from $750 to $24,375. The sole $7.5 million BPA vehicle awarded February 16, 2024, runs through February 15, 2029, anchoring forward revenue potential but subject to HRSA's year-to-year task order issuance discipline. No subcontract footprint exists; all awards are performed by Leist Thomas P directly. The vendor's business model is entirely dependent on continuous HRSA task order flow for individual vaccine injury cases; absence of diversification across agencies, vehicles, or contract types creates significant customer-concentration and revenue-stability risk.